TitleMutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.
Publication TypeJournal Article
Year of Publication2015
AuthorsShih, Alan H., Jiang Yanwen, Meydan Cem, Shank Kaitlyn, Pandey Suveg, Barreyro Laura, Antony-Debre Ileana, Viale Agnes, Socci Nicholas, Sun Yongming, Robertson Alexander, Cavatore Magali, de Stanchina Elisa, Hricik Todd, Rapaport Franck, Woods Brittany, Wei Chen, Hatlen Megan, Baljevic Muhamed, Nimer Stephen D., Tallman Martin, Paietta Elisabeth, Cimmino Luisa, Aifantis Iannis, Steidl Ulrich, Mason Chris, Melnick Ari, and Levine Ross L.
JournalCancer Cell
Volume27
Issue4
Pagination502-15
Date Published2015 Apr 13
ISSN1878-3686
KeywordsAntineoplastic Agents, Cell Differentiation, Cytarabine, Dioxygenases, DNA Methylation, DNA-Binding Proteins, Doxorubicin, Epigenesis, Genetic, fms-Like Tyrosine Kinase 3, GATA2 Transcription Factor, Gene Expression Regulation, Neoplastic, Gene Silencing, Haploinsufficiency, Leukemia, Myeloid, Acute, Mutation, Proto-Oncogene Proteins
Abstract

<p>Specific combinations of acute myeloid leukemia (AML) disease alleles, including FLT3 and TET2 mutations, confer distinct biologic features and adverse outcome. We generated mice with mutations in Tet2 and Flt3, which resulted in fully penetrant, lethal AML. Multipotent Tet2(-/-);Flt3(ITD) progenitors (LSK CD48(+)CD150(-)) propagate disease in secondary recipients and were refractory to standard AML chemotherapy and FLT3-targeted therapy. Flt3(ITD) mutations and Tet2 loss cooperatively remodeled DNA methylation and gene expression to an extent not seen with either mutant allele alone, including at the Gata2 locus. Re-expression of Gata2 induced differentiation in AML stem cells and attenuated leukemogenesis. TET2 and FLT3 mutations cooperatively induce AML, with a defined leukemia stem cell population characterized by site-specific changes in DNA methylation and gene expression.</p>

DOI10.1016/j.ccell.2015.03.009
Alternate JournalCancer Cell
PubMed ID25873173
PubMed Central IDPMC4518555
Grant ListR01 CA173636 / CA / NCI NIH HHS / United States
R01 CA166835 / CA / NCI NIH HHS / United States
R01 CA166429 / CA / NCI NIH HHS / United States
R01CA166835 / CA / NCI NIH HHS / United States
U10 CA021115 / CA / NCI NIH HHS / United States
U24 CA196172 / CA / NCI NIH HHS / United States
R01NS076465 / NS / NINDS NIH HHS / United States
R01HG006798 / HG / NHGRI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
R01 HG006798 / HG / NHGRI NIH HHS / United States
R01 CA169784 / CA / NCI NIH HHS / United States
CA172636-01 / CA / NCI NIH HHS / United States
U10 CA180820 / CA / NCI NIH HHS / United States
R01 NS076465 / NS / NINDS NIH HHS / United States
P30 CA013330 / CA / NCI NIH HHS / United States
U10 CA180827 / CA / NCI NIH HHS / United States